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DuctalCarcinomainsituhasbeendiagnosedmorefrequentlyinthelastfewyearsandnowaccountsforapproximately one-fourth
of all treated breast cancers. Traditionally, this disease has been treated with total mastectomy, but conservative surgeryhas become
increasinglyusedintheabsenceofunfavourableclinicalconditions,ifanegativeexcisionmargincanbeachieved.Itiscontroversial
whether subgroups of patients with favourable in situ tumors could be managed by conservative surgery alone, without radiation.
As the disease is diagnosed more frequently in younger patients, these issues are very relevant, and much research has focused on
this topic in the last two decades. We reviewed randomized trials regarding adjuvant radiation after breast-conservative surgery
and compared data with available retrospective studies.
1.Introduction
Ductal carcinoma in situ (DCIS) is the fourth leading cancer
among women in the United States, and its incidence has
dramatically increased since the introduction of screening
mammography. In the last 30 years we have witnessed a
fourfold increase in its incidence [1], so that approximately
one-ﬁfth of all screen detected breast cancers are diagnosed
as DCIS [2]. The relevance of this problem is evidenced by
thelargeamountofdataavailableintheliterature,withmore
than 10,000 articles published on the issue, so far [3].
Interestingly, while the incidence of DCIS is increasing
at a 15% annual rate in all age groups, the incidence of
invasive breast cancer has been decreasing along with overall
mortality for breast cancer [4].
Standard of care for surgical treatment of DCIS has
long been represented by total mastectomy, with cure rates
approaching 100%. Mastectomy remains indicated if the
disease is too extensive to be resected with a good cosmetic
outcome, in the case of inability to achieve negative margins,
in the case of micropapillary DCIS or DCIS with nipple
discharge, or if there are contraindications to radiotherapy
(RT) in high-risk patients.
However, as breast conservation has been demonstrated
equivalent to mastectomy for breast cancer patients in terms
of overall survival in 6 prospective-randomized trials [5],
conservative approaches have become appealing for this
preinvasive disease.
It is evident that the search for the appropriate surgical
treatment of DCIS is strategic, because while the disease
is often multifocal, approximately 40% of recurrences are
invasive [6]. Additionally, DCIS is oftendiagnosed in women
during the “active” years of their lives, as approximately half
of them become aware of this disease before the age of 60 [7],
and roughly one-third before the age of 50 [3]. Therefore,
while prevention of LR is a major goal of the treatment of
DCIS if one wishes to maintain this disease always curative,
the need to maintain a good body image for these patients
cannot be understressed.
As our knowledge and understanding of DCIS has
evolved in the last decades, the treatment decision-making
processhasbecomeincreasinglycomplex,anditremainsone2 International Journal of Surgical Oncology
Table 1: Randomized trials results of excision with or without RT.
Trials NSABP B-17 EORTC 10853 UKCCR SWE-DCIS
Patients 818 1010 1030 1046
Date 1985–1990 1986–1996 1990–1998 1987–1999
Median F/U (years) 12 10.2 4.3 5.2
Central path review (%) 76 85 79 20
LR with RT (%) 15.7 15 5.6 7
LR w/o RT (%) 31.7 26 13.6 22
Legend: F/U: followup; LR: local recurrence; w/o: without.
of the most controversial aspects in breast cancer treatment.
This is well evidenced by a recent report on treatment of
DCIS in the United States, describing that at the present time
30% of women with DCIS are treated with mastectomy, 40%
with conservative surgery plus RT, and 30% with excision
alone [8]. Additionally, data on treatment trends for DCIS in
the USA have documented a shift in the last 15 years with a
decrease of mastectomy in favour of breast conservation plus
RT [3].
Breast conservation for DCIS is an issue of particular
relevance and interest, because it is well documented that, on
the other hand, mastectomy rates are on the rise in the USA
as in other parts of the world [9]. Furthermore, a threefold
increaseofcontralateral“prophylactic”mastectomyhasbeen
reported in the last decade [10], and it is recognized that
DCIS is a marker for increased risk of invasive carcinoma in
both breasts [11].
Several clinical factors may help to explain the tendency
to implement this approach, including a more liberal use of
MRI in the last few years with appreciation that the disease
may be more extensive than previously recognized [12], and
adoption of “conservative” mastectomies with immediate
reconstruction, including nipple-sparing approaches.
The aim of the present report is to critically analyze
data from randomized trials for DCIS and to compare their
conclusions with data from retrospective series.
2.RandomizedTrials
Five prospective randomized trials were reported in the last
two decades regarding adjuvant treatment after surgery for
DCIS. Four of them focused on the need of adjuvant RT after
conservative surgery (Table 1), while two also investigated
the addition of tamoxifen to lumpectomy plus RT.
2.1. NSABP B-17. In NSABP B-17 [13] 818 women with
DCIS were randomized to undergo either lumpectomy only
(n = 403)orlumpectomyfollowedbybreastirradiation(n =
410) to a total dose of 50Gy (9% of patients received 10Gy
boost to the tumor bed). Histologically negative surgical
margins were required in both groups, however inking of
marginswasnotroutinelyused.Theﬁve-yearoutcomeswere
ﬁrst reported in 1993 [14] showing a 60% lower risk of
ipsilateral breast tumor recurrence for patients who received
RT. Subsequent updates continued to demonstrate a large
beneﬁt for lumpectomy plus radiotherapy compared with
lumpectomy [15]. The 12-year local recurrence rate was
15.7% among women who underwent breast irradiation and
31.7% among women treated by lumpectomy alone (P =
0.000005).
2.2. EORTC 10853. In a similar trial from EORTC [16]
1010 women with DCIS were randomized to undergo either
lumpectomy only (n = 503) or lumpectomy followed by
breast irradiation (n = 507) to a total dose of 50Gy.
Histological negative surgical margins were required in both
groups. However, at central pathology review margins were
close (<1mm) or involved in 8.5% of patients. At 10 years,
patients treated with local excision alone had a LR rate of
26%, compared with 15% of LR rate in the group of excision
plus RT (P<0.0001).
2.3.SWE-DCIS. IntheSweDCIStrial[17]1067womenwere
randomly assigned to excision plus RT (n = 526) or excision
only (n = 520). RT was administered continuously with
50Gy in 25 fractions, or as a split course treatment with
54Gy in two series with a gap of two weeks. No boost to
the tumor bed was ever used. Microscopically clear margins
were not mandatory. After a median followup of 5.2 years
thecumulativeincidenceofLRwas22% inthecontrolgroup
and 7% in the RT group. No diﬀerences were observed in the
two groups for metastases or breast cancer deaths.
2.4. UK/ANZ. In the UK/ANZ trial 1701 patients were
randomly assigned to RT, and/or tamoxifen (TAM), using
a two by two factorial design between 1990 and 1998 [18].
This created four subgroups: excision alone, excision plus
RT, excision plus TAM, and excision plus RT plus TAM. At a
median followup of 4.4 years the rate of local recurrence was
5.6% in the group with RT and 13.6% in the group without
RT (P<0.0001). Rate of LR was not found to be signiﬁcant
if tamoxifen was added to RT.
2.5. NSABP B-24. Another large randomized study (NSABP
B-24) [13] investigated the addition of tamoxifen to lumpec-
tomy plus radiotherapy in a cohort of 1804 patients treated
between 1991 and 1994. The 7-year LR rate was 11.1% in
the group treated with placebo and 7.7% in the group with
tamoxifen (P = 0.02). This represented a 31% reduction
in the risk of ipsilateral breast recurrences. Tamoxifen also
accounted for a 53% risk reduction of contralateral breast
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signiﬁcant increase in the incidence of endometrial cancer in
the tamoxifen group (0.78% to 0.33%; P = 0.38).
3.Meta-Analysis
A recent meta-analysis of the four randomized trials on
radiation therapy for DCIS [19] showed that the LR rates
were 4.79% (82/1711) and 11.3% (221/1954) for the RT and
the observation arm, respectively.
The analysis showed a 60% reduction of risk of invasive
and DCIS ipsilateral breast cancer with adjuvant RT.
Whiletheincidenceofipsilateralbreastcancerrecurrence
did not diﬀer in the two groups, there were more invasive
ipsilateral breast cancers in the observation group (8.1%)
compared to the RT arm (3.8%).
The likelihood of contralateral breast cancer was 1.53-
fold higher (3.85% versus 2.5%, P = 0.03) in RT arm.
The meta-analysis was not able to identify a subgroup
of women who would not need RT, although the absolute
magnitude of beneﬁt was greater in the groups at higher
risk for local failure, such as young patients and those with
clinically evident lesions.
Another recent meta-analysis by the Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG) analyzed individ-
ual patient data for all four randomized trials [20]. A
total of 3729 remained eligible for the analysis after the
exclusion of patients with microinvasion, invasion, Paget’s
disease, or another cancer present at the time of initial
diagnosis. Radiotherapy reduced the absolute 10-year risk
of any ipsilateral breast event by 15.2% (P<0.00001), and
it was eﬀective regardless of the age at diagnosis, use of
tamoxifen, margin status, focality, grade, comedonecrosis,
architecture, or tumor size.
Furthermore, the proportional reduction in ipsilateral
breasteventswasgreaterinolderthaninyoungerwomenbut
did not diﬀer signiﬁcantly according to any other available
factor.
Even for women with negative margins and small low-
grade tumors, the absolute reduction in the 10-year risk of
ipsilateral breast events was 18.0% (2P = 0.002). After 10
years of followup, there was, however, no signiﬁcant eﬀect
on breast cancer mortality, mortality from causes other than
breast cancer, or all-cause mortality.
4. Discussion
Results of these important randomized trials have been used
to justify RT for all women with this disease.
Of course, RT is time consuming for the patients, may
be responsible for several local side eﬀects, and its avoidance
would be desirable in patients with a low risk of recurrence.
Additionally, it is well recognized that RT is associated with
higher rates of complications if a mastectomy and breast
reconstruction are needed in case of relapse [21, 22].
Relapse after treatment of DCIS is not rare, and a 9.8%
incidenceofinvasiveipsilateralsecondeventswasreportedin
a recent analysis of 3046 patients from the Cancer Registry of
Norway, with a median followup of 5 years [23]. An analysis
of the outcome of 150 patients with LR after treatment for
DCIS showed that 63 of them were invasive, and that the risk
of death from breast cancer was 12% in that group [24].
There are several problems regarding the design of these
four randomized trials. Pathologic factors aﬀecting local
control were largely unrecognized when these studies were
designed and initiated.
Roughly 70% of women were randomized and treated
before 1995, an era when both diagnosis and treatment was
very diﬀerent from current standards. Wide free margins
and mammography of the excised breast tissue are now
standard practice among dedicated surgeons, and whenever
a positive surgical margin is found at ﬁnal pathology, a
reexcision is usually recommended. Neither mammography
of the surgical specimen to conﬁrm excision of all micro-
calciﬁcation,nornegative margins ofexcisionwereamanda-
tory achievement in three of the four trials. Furthermore,
MRI was not an option for these women, and therefore
patients were included in the study even if radiologic
evidence of multifocality by current standards could not
be excluded. Finally, we have entered an era of increasing
awareness among women and diagnosis of smaller tumors is
more often reported. Outcome of screening-detected DCIS
treated with excision alone may be more favourable, and
although recurrence rates of 15% at 5 years are reported,
theseareoftensuccessfullysalvagedwithbreastconservation,
with overall breast-speciﬁc survival of 99% [25].
In NSABP B-17 histologically negative surgical margins
were required. However inking of margins was not routinely
used and in 13% of cases margins were either involved
or unknown. NSABP B-24 allowed entry of women with
involved tumor margins and women whose mammograms
showedresidualcalciﬁcationsaslongastheywereconsidered
not suggestive of invasive cancer. In fact, in this trial
approximately one quarter of patients had either involved or
uncertain tumor margin status. In the EORTC trial, central
pathology review of margins showed that they were close
(<1mm) or involved in 16% of patients. In the Swe-DCIS
trial microscopically clear margins were not mandatory, and
approximately 10% of patients had pathologically involved
margins.
Furthermore, in NSABP B17 both DCIS and lobular
carcinoma in situ were considered eligible. Treatment of
lobular carcinoma in situ is very diﬀerent today, as we
recognizeitasadiﬀerentpathologicalentityfromDCIS,with
diﬀerent risks of relapse and issues for local control, at least
for the low- and intermediate-grade varieties.
These problems limit the ability to apply the results of
these trials to patients who undergo what is now considered
optimal surgery with total pathologic evaluation. In fact
patients with positive margins appeared to beneﬁt the most
from adjuvant radiation therapy, and this has been proposed
as a possible explanation for the diﬀerences between these
trials and other retrospective experience [26].
Furthermore, preoperative evaluation of the extent of
disease is changing, an important issue given the ﬁnding of
theUKSloanProjectthatin30%ofpatientsundergoingBCS
for DCIS preoperative imaging underestimates the extent of
disease,resultinginarequirementforfurthertreatment[27].4 International Journal of Surgical Oncology
Silverstein reported his experience and found that in
patients without RT, and with a careful pathological evalu-
ation and achievement of negative margins of almost 1cm in
all direction, LR rates were comparable to those of patients
treated with RT in those randomized trials [28].
In a classic work from Silverstein [28] the 10-year
actuarial LR rates after BCS with or without RT were 20%
and 28%, respectively (P = 0.06). It is noteworthy that
more patients had close (<1mm) margins in the RT group
compared to the group treated with excision alone (35%
versus 19%).
In this study tumor size, nuclear grade, margin width,
comedonecrosis and patient age were predictors of local
recurrence. This ﬁnding is very similar to a recent meta-
analysis involving 44 studies on the tumor characteristics as
predictors of local recurrence after treatment of DCIS [29].
Silverstein incorporated these predictors in a prognostic
index called the Van Nuys Prognostic Index (USC/VNPI),
designed as a scoring system to support patients and
clinicians regarding the need for adjuvant RT [28]. It was
suggested that patients with low USC/VNPI scores (4 to 6)
could be treated with excision alone, while patients with
intermediate scores (7 to 9) showed an average of 10 to
15% LR beneﬁts with the addition of RT after BCS. Patients
with high score (>10) seem to be unsuitable for BCS (as
recurrences are high with or without RT) and should be
considered for total mastectomy.
Unfortunately, this scoring system has never been vali-
dated by prospective studies, and some feel that although the
authors demonstrate a high level of dedication and expertise
in the treatment of this disease, reproducibility in clinical
practice has never been demonstrated.
In an attempt to clarify this controversy and to assess the
role of documented free margins and the reproducibility of
Silverstein’s experience, the Eastern Cooperative Oncology
Group (ECOG) designed a prospective single arm study of
excision alone in 671 selected patients with DCIS whose
diameter was less than 2.5cm if low-grade, or less than
1cmifhigh-grade[30].Surgicalspecimensweresequentially
sectioned and completely embedded to determine tumor
size, grade, and the margin status, stratifying patients
on tumor grade and intention to administer tamoxifen.
Postexcision magniﬁcation mammography was also always
performed to document removal of all calciﬁcations.
In the high-grade DCIS the rate of ipsilateral recurrence
was 15.3%, suggesting excision alone is associated with a
high risk of local recurrence for high-grade DCIS, even
if wide (almost 3mm) surgical margins are required. In
the low-/intermediate-grade group however, the 5-year rate
of ipsilateral breast events was 6.1%, a result which could
be considered acceptable by many patients and physicians.
Results were even more favourable for tumors less than
10mm in diameter, or for patients >45 years of age.
However, it is well recognized that while local relapse
aftertreatmentoflow-gradeDCISmaytakelongertopresent
clinically compared to high-grade lesions, its incidence
deﬁnitely approaches the latter group with longer follow-
up [31]. Therefore, interpretation of this data necessitates
caution, and more time is needed to conﬁrm the ﬁnding of
this trial.
Another prospective study on 158 patients with predom-
inantly grade 1 or 2 lesions treated exclusively with surgery
without RT [32], was recently presented by Wong et al. The
protocol required a margin width of 1cm or more. The 5-
year local recurrence rate was 12%, and 31% of the recur-
rences were invasive, resulting in premature closure of the
study.
As t u d yo fw o m e nw i t hl o w - g r a d eD C I St r e a t e dw i t h
biopsy alone from 1950 to 1968 and observed for a long
period of time is not only of historical interest. Even
this study showed a risk of developing invasive cancer for
ipsilateral relapse in 30% of cases at 15 years [33].
Recently, a long-term follow-up evaluating invasive
ipsilateral breast recurrence among participants in the two
NABP trials (NSABP B17 and B24) has been published [34].
This is an important study because these two trials remain
the largest prospective evaluation of breast conservation for
DCIS to date. While 54% of local failures were invasive,
the 15-year risk of this event was 19.4% for local excision,
and 8.9% for local excision plus radiation. Compared with
women aged 65 years and older, women younger than 45
years showed a 2.1-fold increase of invasive recurrences.
Similarly, the margin status in NSABP B24 was associated
with an approximately twofold increase of invasive recur-
rence.Overall,breast-cancermortalitydidnotdiﬀerbetween
patients who received RT and those who did not. However,
women who developed an ipsilateral invasive recurrence had
a 1.75-fold greater risk of death compared with those who
did not, and a 7.06-fold greater risk of breast cancer-related
deaths.
Therefore, the main issue in treating DCIS is the preven-
tion of invasive relapses, because not all of them will be
curable. No doubts, our attention is directed towards the
identiﬁcation of subgroups of patients (e.g., those with low
grade tumors, age >60, adequate margins) that could avoid
RT after surgical treatment of DCIS, and in the last 2
years many reports and Consensus statements have focused
on this, including the Saint Gallen Consensus Conference
[35], the Newport Consensus Conference III [36], and the
National Consensus Cancer Network [37].
However, from a very practical point of view, even
the width of surgical margin remains controversial for the
treatment of DCIS, and while the “Consensus on DCIS of
Philadelphia” has proposed a 10mm margin [38], others
h a v ep r o p o s e dm a r g i n so f1t o3m ma sa d e q u a t e[ 39].
Another controversial issue regarding DCIS is whether
patients with DCIS beneﬁt from tamoxifen. While it is well
known that women with hormone-receptor positive invasive
breast cancer beneﬁt from the addition of tamoxifen, its role
on local control after excision of DCIS is not well quantiﬁed.
In NSABP-B-24 trial [13], the addition of tamoxifen
resulted in a risk reduction of 16% compared with RT +
placebo (HR = 0.84, 95% CI = 0.60 to 1.19, P = 0.33),
while the UKCCCR trial [18] found a nonsigniﬁcant eﬀect
in regard of all breast events.
Thediﬀerentﬁndingsinthesetwotrialsmaybetheresult
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there was a higher proportion of young patients, ER positive,
and low-grade DCIS with respect to those of UKCCCR.
Furthermore, NSABP B-24 included patients with positive
margins. This could in part explain the discrepancies in the
outcomes between the group with tamoxifen and the group
with placebo.
Therefore, the question remains of whether there are
subgroups of patients for whom RT or tamoxifen is more or
less eﬀective in terms of absolute risk reduction.
Few trials were designed to clarify this important issue.
RTOG 9804 and the UK DCIS II trials are both designed
to compare RT plus endocrine therapy with endocrine
therapy alone for low-risk DCIS (grades 1-2 up to 3cm with
clear margins of at least 3mm).
RTOG 9804 accrued 636 patients out of a target of 1790,
and has been recently closed. The results of these trials
will provide further information on the eﬃcacy of excision
alone and may allow the development of criteria to identify
subgroups of patients who may not require adjuvant RT.
5. Ongoing Trials
Althoughmanyquestionsremainopendespitetheincreasing
interest in this disease, it is reassuring that there are many
ongoing clinical trials to clarify several aspects regarding
treatment of DCIS (see http://www.clinicaltrials.gov/ for
further information).
The role of MRI in the diagnosis and evaluation of
the extent of DCIS will be assessed in several small trials
sponsored by the Memorial Sloan-Kettering Cancer Center,
the University of California at San Francisco, and in Europe
by the Centre Lacassagne in Nice.
Wide excision alone in grades 1-2 DCIS less than
2.5cm in diameter is being investigated by a phase II trial
sponsored by the Dana-Farber Cancer Institute. Similarly,
the UK ICR-DCIS-II study is studying adjuvant RT after
surgery for hormone-responsive DCIS receiving tamoxifen
or anastrozole. This is a randomized trial with a target
accrual of 2000 patients started in 2004.
Diﬀerent radiation approaches are being investigated by
several trials. Targeted intraoperative RT (20Gy to surface
of tumor bed) is being evaluated at the USC/Norris Com-
prehensive Cancer Center in 116 patients, and the estimated
completion date is 2013. The role of a boost to the tumor
bed is currently studied in a phase III multicentric trial
in France, with a projected enrollment of 1950 patients.
Hypofractionation is being studied by a randomized trial
sponsored by MD Anderson Cancer Center comparing
conventional whole-breast radiation to 42Gy in 16 fractions
and a boost of 10Gy in 4 fractions. Estimated enrolment is
200 patients with an expected completion date by 2014.
NSABP B35 is a randomized trial, with a target of 3100
patients, comparing tamoxifen versus anastrozole in the
treatment of postmenopausal women with DCIS; results will
be available in 2016.
NSABP B-43 is a randomized trial investigating the role
of adjuvant Trastuzumab in women after lumpectomy and
RT; completion is estimated in 2019. Finally, neoadjuvat
approaches, including the use of Aromatase Inhibitor in
hormone-positive DCIS, and of Herceptin in neu + DCIS are
currently being investigated.
6. Conclusions
Based on available evidence obtained from prospective
clinical trials, patients with DCIS have potential beneﬁt from
RT after BCS with up to 60% risk reduction for ipsilateral
recurrence.
However, the natural history of DCIS after surgical
treatment is very variable, and the balance between beneﬁt
a n dr i s ko fR Tm a yd i ﬀer in patients with low- and high-risk
disease.
T h eu l t i m a t eg o a li nt r e a t i n gD C I Sm a yb et oa c c u r a t e l y
identify which patients can safely omit adjuvant RT because
their risk of developing a potential life-threatening relapse
with invasive carcinoma is low. Actually, there is no evidence
from randomized or prospective trials that it is possible to
deﬁnealow-riskgroupofpatientsforwhomRTcanbesafely
avoided.
Finally, although we may identify low-risk patients, the
potential impact of LR after conservative treatment of DCIS,
and its physical and psychological consequences must be
properly and individually considered, as the ultimate goal of
treatment may be diﬀerent for diﬀerent patients.
Many controversial issues on DCIS will probably be
resolved if molecular predictors of progression and relapse
to invasive carcinoma can be identiﬁed.
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